COSM vs NUS
Cosmos Health Inc. and NU Skin Enterprises, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | COSM | NUS |
|---|---|---|
| Revenue | $65.3M | $1.5B |
| Net income | $-19.1M | $160.2M |
| Gross margin | 12.1% | 69.4% |
| Net margin | −29.3% | 10.8% |
| Return on equity | −89.1% | 22.0% |
| Diluted EPS | −$0.63 | $3.18 |
| Dividend / share | · | · |
| Payout ratio | · | 7.4% |
| Free cash flow | $-8.5M | $46.0M |
| Equity | $18.4M | $805.2M |
| Net debt / equity | 0.17× | −0.02× |
| Current ratio | 1.00× | 2.08× |
| Revenue CAGR 5y | 3.3% | −10.5% |
| Profit CAGR 5y | · | −3.5% |
NUS bills 22.8× the revenue of COSM, and COSM closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | COSM | NUS |
|---|---|---|
| FY2025 | $65.3M | $1.5B |
| FY2024 | $54.4M | $1.7B |
| FY2023 | $53.4M | $2.0B |
| FY2022 | $50.3M | $2.2B |
| FY2021 | $56.2M | $2.7B |
| FY2020 | $55.4M | $2.6B |
| FY2019 | $39.7M | $2.4B |
| FY2018 | $37.1M | $2.7B |
| FY2017 | $30.0M | $2.3B |
| FY2016 | $6.8M | $2.2B |
Bottom line
| Fiscal year | COSM | NUS |
|---|---|---|
| FY2025 | $-19.1M | $160.2M |
| FY2024 | $-16.2M | $-146.6M |
| FY2023 | $-18.5M | $8.6M |
| FY2022 | $-13.8M | $104.8M |
| FY2021 | $-8.0M | $147.3M |
| FY2020 | $820,786 | $191.4M |
| FY2019 | $-3.3M | $173.6M |
| FY2018 | $-9.1M | $121.9M |
| FY2017 | $-6.2M | $129.4M |
| FY2016 | $-601,002 | $143.1M |
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$1,419,887,185 | NUS |
| FY2024 | −$1,677,657,598 | NUS |
| FY2023 | −$1,915,754,126 | NUS |
| FY2022 | −$2,175,311,348 | NUS |
| FY2021 | −$2,639,429,333 | NUS |
| FY2020 | −$2,526,527,663 | NUS |
| FY2019 | −$2,380,739,615 | NUS |
| FY2018 | −$2,641,924,118 | NUS |
| FY2017 | −$2,249,085,621 | NUS |
| FY2016 | −$2,201,041,564 | NUS |
| FY2015 | −$2,246,513,198 | NUS |
| FY2014 | −$2,561,855,978 | NUS |
| FY2013 | −$3,175,815,631 | NUS |
NUS has reported the higher revenue in every one of these 13 fiscal years. The gap has narrowed since the earliest year compared.
13 of 17 comparable fiscal years — a year missing data on either side is not counted.
13 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −40.1 pp | NUS |
| FY2024 | −21.3 pp | NUS |
| FY2023 | −35.2 pp | NUS |
| FY2022 | −32.2 pp | NUS |
| FY2021 | −33.2 pp | NUS |
| FY2020 | −5.9 pp | NUS |
| FY2019 | −15.5 pp | NUS |
| FY2018 | −29.0 pp | NUS |
| FY2017 | −26.4 pp | NUS |
| FY2016 | −15.4 pp | NUS |
| FY2015 | −1258.8 pp | NUS |
| FY2014 | +71.8 pp | COSM |
| FY2013 | +15.8 pp | COSM |
The higher net margin has changed hands between COSM and NUS over this period.
13 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
COSM's net margin has been more volatile than NUS's over the 13 comparable fiscal years — 332.9 percentage points of standard deviation against 4.8.
13 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between COSM and NUS over these 13 fiscal years — COSM led in 2 and NUS in 11.
13 of 17 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
COSM's return on equity has been more volatile than NUS's over the 4 comparable fiscal years — 15.5 percentage points of standard deviation against 15.5.
4 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
NUS led in return on equity in every one of the 4 comparable fiscal years — a structural lead, not a recent swing.
4 of 18 comparable fiscal years — a year missing data on either side is not counted.